Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Oct;14(10):1030-7.
doi: 10.1007/s00520-006-0062-5. Epub 2006 Jun 27.

Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer

Philippe Fagnoni  1 , Samuel Limat, Loïc Chaigneau, Emmanuel Guardiola, Stéphanie Briaud, Bernard Schmitt, Yacine Merrouche, Xavier Pivot, Marie-Christine Woronoff-Lemsi
Affiliations

Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer

Philippe Fagnoni et al. Support Care Cancer. 2006 Oct.

Abstract

Introduction: Anaemia is a common toxicity in cancer patients and epoetins (EPOs) are now an established treatment. The economic profile of EPO treatment was assessed in patients with breast cancer treated by adjuvant-chemotherapy.

Materials and methods: Two strategies were compared: without treatment by EPO and with the possible use of treatment by EPO (epoetin alfa) when required. The clinical effectiveness criterion was time adjusted to quality of life and economic data included only direct medical costs.

Main results: One hundred ninety-two patients were included. In the group with the strategy containing the possible use of EPO, 45.5% of patients effectively received EPO. A significant difference in the haemoglobin level profile over time was observed which provided a significant overall benefit of 0.0052 (p<10(-4)) quality-adjusted life year (QALY) associated with an extra cost of <euro>1,615 (p<10(-4)). In the base case analysis, the cost per added QALY was estimated as <euro>310,577 with the strategy containing the possible use of EPO.

Conclusion: This robust result seems to be unacceptable, but the only relevant point of discussion might be the level of acceptable incremental cost-effectiveness ratio (ICER) for a patient.

PubMed Disclaimer

References

    1. Ann Oncol. 1998 Mar;9(3):255-60 - PubMed
    1. Ann Oncol. 1993 Feb;4(2):161-7 - PubMed
    1. J Clin Oncol. 1997 Mar;15(3):1218-34 - PubMed
    1. Pharmacoeconomics. 1997 Jan;11(1):19-31 - PubMed
    1. Pharmacoeconomics. 1993 Jan;3(1):45-82 - PubMed

MeSH terms

LinkOut - more resources